Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3001568 | 0.88 | BRAF (0.53) | BRAFTNNI3KSYKMEN1KMT2A | |
| SCHEMBL2995190 | 0.85 | BRAF (0.52) | BRAFTNNI3KSYKCAMK2D | |
| SCHEMBL2995233 | 0.85 | BRAF (0.51) | BRAFTNNI3K | |
| SCHEMBL24862147 | 0.85 | BRAF (0.40) | BRAFTNNI3KLMNA | |
| SCHEMBL3001378 | 0.84 | NFKB1 (0.46) | MEN1MAPTKMT2A | |
| SCHEMBL5839451 | 0.82 | SYK (0.47) | SYKMAPT | |
| SCHEMBL30719583 | 0.82 | NPC1 (0.54) | SYKLMNA | |
| SCHEMBL5839044 | 0.82 | BRAF (0.54) | BRAFMAPT | |
| SCHEMBL3004036 | 0.82 | NPC1 (0.54) | SYKLMNA | |
| SCHEMBL7108109 | 0.81 | TOP2A (0.55) | KDM4EMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315747-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | BRAF 88/4885TNNI3K 183/4885SYK 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.